Dynavax Technologies (NASDAQ:DVAX) Rating Lowered to C+ at TheStreet – MarketBeat
Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
Dynavax Technologies (NASDAQ:DVAX – Get Rating) was downgraded by TheStreet from a “b-” rating to a “c+” rating in a research report issued to clients and investors on Thursday, TheStreetRatingsTable reports.
Separately, StockNews.com raised Dynavax Technologies from a “hold” rating to a “buy” rating in a research report on Friday, August 5th. One equities research analyst has rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat.com, Dynavax Technologies presently has an average rating of “Moderate Buy” and an average target price of $28.00.
Dynavax Technologies Price Performance
Shares of DVAX opened at $11.21 on Thursday. The company has a current ratio of 2.77, a quick ratio of 2.55 and a debt-to-equity ratio of 0.52. The firm’s fifty day simple moving average is $13.86 and its 200-day simple moving average is $11.89. The firm has a market capitalization of $1.42 billion, a price-to-earnings ratio of 8.01 and a beta of 1.30. Dynavax Technologies has a twelve month low of $7.26 and a twelve month high of $21.39.
Insider Activity at Dynavax Technologies
In other Dynavax Technologies news, COO David F. Novack sold 26,250 shares of the firm’s stock in a transaction dated Tuesday, August 9th. The stock was sold at an average price of $16.92, for a total transaction of $444,150.00. Following the transaction, the chief operating officer now owns 53,213 shares of the company’s stock, valued at $900,363.96. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other Dynavax Technologies news, SVP Robert Janssen sold 7,938 shares of Dynavax Technologies stock in a transaction on Tuesday, August 9th. The shares were sold at an average price of $16.92, for a total value of $134,310.96. Following the transaction, the senior vice president now directly owns 35,519 shares in the company, valued at $600,981.48. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, COO David F. Novack sold 26,250 shares of the stock in a transaction dated Tuesday, August 9th. The stock was sold at an average price of $16.92, for a total transaction of $444,150.00. Following the sale, the chief operating officer now owns 53,213 shares of the company’s stock, valued at approximately $900,363.96. The disclosure for this sale can be found here. Insiders sold a total of 64,109 shares of company stock valued at $1,088,474 over the last ninety days. Insiders own 9.31% of the company’s stock.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently made changes to their positions in the company. American Century Companies Inc. grew its stake in Dynavax Technologies by 54.7% in the 4th quarter. American Century Companies Inc. now owns 82,990 shares of the biopharmaceutical company’s stock worth $1,168,000 after acquiring an additional 29,344 shares during the period. ProShare Advisors LLC grew its holdings in Dynavax Technologies by 70.6% in the 4th quarter. ProShare Advisors LLC now owns 23,556 shares of the biopharmaceutical company’s stock valued at $332,000 after buying an additional 9,747 shares during the period. Raymond James & Associates acquired a new position in shares of Dynavax Technologies during the 4th quarter valued at about $153,000. Bank of America Corp DE lifted its holdings in shares of Dynavax Technologies by 356.1% during the 4th quarter. Bank of America Corp DE now owns 322,762 shares of the biopharmaceutical company’s stock worth $4,541,000 after acquiring an additional 251,995 shares during the period. Finally, Lazard Asset Management LLC acquired a new stake in shares of Dynavax Technologies in the fourth quarter worth approximately $721,000. Institutional investors and hedge funds own 96.66% of the company’s stock.
About Dynavax Technologies
(Get Rating)
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.
Read More
- Get a free copy of the StockNews.com research report on Dynavax Technologies (DVAX)
- Could Snap Stock Rebound As Management Restructures?
- MarketBeat: Week in Review 8/29 – 9/2
- Hormel Looks Cheap At These Levels
- Lululemon Set To Soar Into September
- Could Nike Stock be Oversold, but Still Overvalued?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Dynavax Technologies, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Dynavax Technologies wasn’t on the list.
While Dynavax Technologies currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Complete the form below to receive the latest headlines and analysts’ recommendations for your stocks with our free daily email newsletter:
Tom remains optimistic about investors’ prospects going forward, even as the market reacts to the words of Fed Chair Jerome Powell about “pain ahead.”
Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat’s trending stocks report.
Identify stocks that meet your criteria using seven unique stock screeners. See what’s happening in the market right now with MarketBeat’s real-time news feed. Export data to Excel for your own analysis.
MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.
Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.
Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.
As Featured By:
MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.
Twitter Facebook StockTwits Financial Juice YouTube
© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.
Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds
© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer.